The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Minimal residual disease assessment in colorectal cancer (MiRDA-C).
 
Arvind Dasari
Consulting or Advisory Role - Advanced Accelerator Applications; Hutchison MediPharma; Ipsen; Lexicon; Novartis; Voluntis
Research Funding - Eisai; Guardant Health; Hutchison MediPharma; Ipsen; Merck; Novartis
 
Maen Abdelrahim
No Relationships to Disclose
 
Jared David Acoba
Research Funding - GlaxoSmithKline
 
Krishna Chaitanya Alluri
Stock and Other Ownership Interests - Abbvie; biogen; Celgene; Gilead Sciences
 
Tomislav Dragovich
Research Funding - ARMO BioSciences; Berg Pharma; Bristol-Myers Squibb (Inst); Halozyme (Inst); HolyStone Therapeutics (Inst); Kyowa Hakko Kirin; Medivir; Novocure (Inst); Rgenix
 
Syed Mohammad Ali Kazmi
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
 
Benjamin Leon Musher
Consulting or Advisory Role - Ipsen; Pfizer
Speakers' Bureau - Ipsen
Research Funding - Lokon Pharma
Expert Testimony - AstraZeneca
 
Ryan Sun
No Relationships to Disclose
 
Lucas Wong
Research Funding - Array BioPharma (Inst); Astellas Pharma (Inst); BeiGene (Inst); Exelixis (Inst); FibroGen (Inst); Merck Sharp & Dohme (Inst); Novocure (Inst); PledPharma (Inst); Seer (Inst); Seer (Inst); Seer (Inst); SynCoreBio (Inst); Tesaro (Inst)
 
Y. Nancy You
No Relationships to Disclose
 
Robert Anthony Zaiden
No Relationships to Disclose
 
Scott Kopetz
Stock and Other Ownership Interests - Iylon; Lutris; MolecularMatch; Navire
Consulting or Advisory Role - Abbvie; Amal Therapeutics; AstraZeneca/MedImmune; Bayer Health; Bicara Therapeutics; Boehringer Ingelheim; Boston Biomedical; Carina Biotech; Daiichi Sankyo; EMD Serono; EMD Serono; Endeavor BioMedicines; Flame Biosciences; Genentech; Gilead Sciences; GlaxoSmithKline; HalioDx; Holy Stone Healthcare; Inivata; Ipsen; Iylon; Jacobio; Jazz Pharmaceuticals; Lilly; Lutris; Merck; Mirati Therapeutics; Natera; Novartis; Numab; Pfizer; Pierre Fabre; Redx Pharma; Repare Therapeutics; Servier; Xilis
Research Funding - Amgen (Inst); Array BioPharma (Inst); Biocartis (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Guardant Health (Inst); Lilly (Inst); MedImmune (Inst); Novartis (Inst); Sanofi (Inst)